Asthma

Dupilumab is associated with greater improvement in asthma exacerbations than omalizumab and mepolizumab. Multiple monoclonal antibodies (mAbs) are currently approved for asthma treatment. All of these improve outcomes in asthma patients who cannot be controlled with conventional therapy. However, only limited data is available regarding their comparative effectiveness, thus restricting opportunities to optimize patient selection...

Itraconazole as a treatment for severe persistent asthma results in a reduction in bronchial wall thickness and an improvement in symptoms and pulmonary function. Severe persistent asthma (SPA) represents five to ten percent of the total asthma population. Long-term use of inhaled corticosteroids in SPA can result in fungal colonization and inflammation. Various inflammatory mediators...

Asthma treatment varies dramatically worldwide, and this study provides individual-level reporting on medication use and disease severity across various economic categories. Among non-communicable diseases, asthma is one of the most commonly occurring globally, affecting more than 350 million people. Although most asthma patients are able to receive asthma control, this is not attained in many...

Although section 340B of the Public Health Service Act may be effective in other areas, this study shows that it does not seem to limit health disparities among certain populations of patients with asthma. In the United States, patients from many walks of life can have difficulties paying for medical care and medications that are...

Dupilumab is effective in improving asthma outcomes in patients with coexisting chronic rhinosinusitis and nasal polyps, and it can reduce the need for oral corticosteroids and improve patients’ quality of life. People with asthma also experience chronic rhinosinusitis and nasal polyps  (CRS-NPs), and allergic rhinitis, and they have a higher disease burden and are more...

Ecleralimab administration is a safe intervention in patients suffering from mild atopic asthma, as it is effective in attenuating airway inflammation and allergen-induced bronchoconstriction. Thymic stromal lymphopoietin (TSLP) is an upstream regulator that mediates inflammatory responses, including type 2 inflammation in asthma. Ecleralimab is a neutralizing antibody fragment that works against human TSLP, and was...

Treatment with dupilumab, a monoclonal antibody, significantly improves clinical outcomes and mediates the reversal of persistent airflow obstruction status in patients with uncontrolled asthma. Asthma is associated with airflow obstruction, which is reversible either spontaneously or with the administration of bronchodilators or corticosteroids. Asthma patients with persistent airflow obstruction (PAO) tend to experience worse asthma...

Asthma is now categorized into different types based on a variety of factors. It is no longer considered a single disease. Understanding the differences between each type can help patients manage their condition better. Asthma is an inflammatory lung illness that causes the airways to swell and narrow. Allergens, exercise, colds, or other irritants can...

Learning about asthma remission and management strategies can help you gain control of your condition and maintain better long-term health. As with any chronic medical disease, it is vital to understand its causes, treatments, and associated self-care procedures.  Asthma symptoms can negatively impact your daily life. But, it can go into remission with proper management...